China Criticizes US Tariffs Linked to Fentanyl Crisis at Press Conference

During a press conference held by the Office of China National Narcotics Control Commission on June 19, 2025, Wei Xiaojun, the executive secretary-general, expressed strong disapproval of the US imposing two rounds of tariffs on Chinese products this year using the so-called fentanyl issue as justification. He described these "fentanyl tariffs" as instances of typical bullying behavior that have considerably eroded the trust and dialogue framework crucial for effective anti-drug collaboration between the two nations. Wei highlighted that China maintains one of the most stringent anti-drug policies and enforcement systems globally and has been actively involved in international anti-drug cooperation, providing substantial assistance to the US in managing the fentanyl crisis.

Wei referenced the white paper, "Controlling Fentanyl-Related Substances -- China's Contribution," released by China's State Council Information Office as a clear outline of China's position on the matter. He pointed out that effectively addressing drug problems necessitates tackling both their symptoms and underlying causes. Despite China having a population over 1.4 billion, the ratio of drug users in the country is less than 0.06 percent. In comparison, the US, with its population exceeding 300 million, has over 10 percent involved in drug use, leading to around 80,000 overdose deaths in 2024, mostly linked to opioids, particularly fentanyl.

Wei called for the US to reflect on its strategies, pursue a scientifically-grounded and responsible approach to drug issues, and strive for balanced measures to decrease drug demand right from the source. He criticized the US for ignoring realities and shifting blame onto others, highlighting that this approach has failed to address the problems at hand. According to reports, China has reacted promptly to safeguard its rights and interests in response to these unfounded tariffs.

Wei emphasized the need for mutual respect and cooperation, urging both China and the US to work together to resolve the drug crisis and integrate anti-drug efforts into their bilateral relationship as a positive aspect rather than an impediment. He conveyed his hope that the US would acknowledge China's contributions and make timely corrections to its erroneous practices, aligning more constructively with reality while addressing mutual concerns equally.

He noted that China has continually supported the global anti-drug framework and engaged meaningfully in international decision-making related to drug governance, focused on collaborating on anti-drug initiatives with various regions and countries. The launch of the Counternarcotics Working Group and various meetings aimed at promoting drug intelligence exchanges highlight China's ongoing commitment to addressing drug issues while fostering international cooperation.